Johnson Investment Counsel’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Johnson Investment Counsel’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$354K	–	686
2021 Q3	$354K	Hold	2,000	–	–	﹤0.01%	513
2021 Q2	$323K	Hold	2,000	–	–	﹤0.01%	521
2021 Q1	$343K	Hold	2,000	–	–	0.01%	487
2020 Q4	$439K	Hold	2,000	–	–	0.01%	424
2020 Q3	$332K	Hold	2,000	–	–	0.01%	452
2020 Q2	$228K	Buy	+2,000	New	+$194K	﹤0.01%	528
2020 Q1	–	Sell	-2,000	Closed	-$258K	–	621
2019 Q4	$258K	Buy	+2,000	New	+$193K	﹤0.01%	534

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Johnson Investment Counsel's MRTX Position: Q4 2021 in Review

Johnson Investment Counsel sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 2,000 shares — an estimated $354K sold.

Johnson Investment Counsel first reported a position in MRTX in Q4 2019 and held it in 7 quarters. The position peaked at $439K in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

Johnson Investment Counsel reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Johnson Investment Counsel sold 2,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $354K.
Johnson Investment Counsel first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 7 quarters.
Johnson Investment Counsel's Mirati Therapeutics, Inc. Common Stock position peaked at $439K in Q4 2020.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Johnson Investment Counsel's 13F filing for Q4 2021, filed 15 Feb 2022.